We are live on ! Find out more
PRQR icon

ProQR Therapeutics

23 hedge funds and large institutions have $43.6M invested in ProQR Therapeutics in 2016 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

38.07% more ownership

Funds ownership: 0%38.07% (+38%)

8% less funds holding

Funds holding: 2523 (-2)

14% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 7

25% less capital invested

Capital invested by funds: $58M → $43.6M (-$14.4M)

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

Holders
23
Holders Change
-2
Holders Change %
-8%
% of All Funds
0.57%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
6
Reduced
7
Closed
6
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
CLM
26
ClearBridge LLC (Maryland)
Maryland
-$74K -11,100 Closed
Deutsche Bank
27
Deutsche Bank
Germany
-$9K -1,447 Closed
TRCT
28
Tower Research Capital (TRC)
New York
-$5K -785 Closed
PCM
29
Prelude Capital Management
New York
+$515 +100 New

PRQR Hedge Fund Activity: Q4 2016 in Review

23 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q4 2016, worth a combined $43.6M — down 25% from $58M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of PRQR and 4 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 6 added.

The largest buyer was Redmile Group, adding an estimated $5.16M. The largest seller was Baker Bros. Advisors, cutting an estimated $3.34M.

  • 23 institutional investors held ProQR Therapeutics (PRQR) as of Q4 2016, down from 25 in Q3 2016.
  • Funds reported $43.6M of ProQR Therapeutics stock for Q4 2016, down 25% quarter-over-quarter.
  • 4 funds opened new ProQR Therapeutics positions in Q4 2016 and 6 closed out, a net change of -2 holders.
  • The largest ProQR Therapeutics buyer in Q4 2016 was Redmile Group, an estimated $5.16M added.
  • The largest ProQR Therapeutics seller in Q4 2016 was Baker Bros. Advisors, an estimated $3.34M sold.

Based on aggregated 13F filings for Q4 2016.